62
Participants
Start Date
January 31, 2011
Primary Completion Date
May 17, 2017
Study Completion Date
May 17, 2017
Panobinostat
Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
Ifosfamide
Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
Mesna
On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
Carboplatin
On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
Etoposide
On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
Pegfilgrastim
Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Novartis
INDUSTRY
M.D. Anderson Cancer Center
OTHER